论文部分内容阅读
目的:观察复方鲜竹沥雾化吸入疗法对慢性阻塞性肺疾病患者肺功能指标的影响。方法:132例慢性阻塞性肺疾病患者,随机分为研究组和对照组,各66例。对照组仅行慢性阻塞性肺疾病的常规治疗;研究组在对照组治疗基础上,行复方鲜竹沥雾化吸入治疗。治疗1周。结果:总有效率研究组95.45%,对照组56.06%,2组比较,差异有统计学意义(P<0.01)。治疗后研究组p H、PO2较对照组高,PCO2指数较对照组低,2组比较,差异均有统计学意义(P<0.01)。治疗后研究组的FEV1、FVC以及FEV1/FVC较对照组高,2组治疗后各项指标比较,差异均有统计学意义(P<0.01)。治疗后研究组的FEV1、FVC以及FEV1/FVC较对照组高,2组治疗后各项指标比较,差异均有统计学意义(P<0.01)。治疗后研究组在呼吸困难、肺部啰音的改善率较对照组高,2组比较,差异均有统计学意义(P<0.05)。结论:加用复方鲜竹沥雾化吸入疗法对慢性阻塞性肺疾病治疗效果更优,肺功能指标改善较好,值得临床推广应用。
Objective: To observe the effects of compound fresh bamboo leaching inhalation on pulmonary function in patients with chronic obstructive pulmonary disease. Methods: 132 patients with chronic obstructive pulmonary disease were randomly divided into study group and control group, with 66 cases in each. The control group was treated only routinely with chronic obstructive pulmonary disease. On the basis of the treatment of the control group, the study group was treated with compound fresh bamboo leaching inhalation. Treatment for 1 week. Results: The total effective rate was 95.45% in the study group and 56.06% in the control group. There was significant difference between the two groups (P <0.01). After treatment, the levels of p H, PO2 in the study group were higher than those in the control group, while the PCO2 index was lower in the study group than in the control group. The differences were statistically significant (P <0.01). After treatment, FEV1, FVC and FEV1 / FVC in the study group were higher than those in the control group. There was significant difference between the two groups after treatment (P <0.01). After treatment, FEV1, FVC and FEV1 / FVC in the study group were higher than those in the control group. There was significant difference between the two groups after treatment (P <0.01). After treatment, the improvement rate of the study group in dyspnea and pulmonary rales was higher than that in the control group. There was significant difference between the two groups (P <0.05). Conclusion: The treatment of compound fresh bamboo levination inhalation therapy is more effective in treatment of chronic obstructive pulmonary disease (COPD) and the improvement of pulmonary function is better, which is worthy of clinical application.